semaglutide banned in california 🚨 Alert: Coverage for Obesity Medications at Risk Just two years after Medi-Cal began covering FDA-approved GLP-1 medications for obesity, that coverage is set to end January 2026 — a FDA and Novo Nordisk Warned

~ AlphaMD If youve ever tried to maintain your testosterone replacement therapy (TRT) routine while traveling, you know its not as simple as tossing your meds in a bag and heading to the airport

Recent Developments in May 2026 & Recent Industry Updates:- In May 2025, #BauschHealthandSalixPharmaceuticals announced new findings showing that #Xifaxan (rifaximin) treatment following #OvertHepaticEncephalopathy hospitalization was associated with a reduced risk of 30-day OHE-related rehospitalization

Lastly, the systemic effects of GLP-1RAs, such as body weight loss [103] and potential reduction in muscle mass [104], pose significant challenges for elderly individuals with neurodegenerative diseases

The FDA still allows GLP-1 prescriptions, but only if you also have at least one qualifying health condition linked to your weight

Sources: Cesarec V, et al

R., Tanis, S